KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$11.21 USD
-0.29 (-2.52%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $11.21 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for KalVista Pharmaceuticals, Inc falls in the month of April.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -92.91 | -82.34 | -46.24 | -29.12 | -20.82 |
Depreciation/Amortization & Depletion | 1.71 | 3.13 | 1.22 | 0.71 | 0.38 |
Net Change from Assets/Liabilities | 7.41 | -12.32 | 8.35 | -20.64 | -18.79 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.53 | 13.40 | 6.51 | 4.24 | 2.86 |
Net Cash From Operating Activities | -75.26 | -78.13 | -30.17 | -44.82 | -36.37 |
Property & Equipment | -1.20 | -0.93 | -0.08 | -0.22 | -1.08 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 42.61 | 58.79 | -147.57 | 16.97 | -68.34 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 41.42 | 57.86 | -147.65 | 16.75 | -69.42 |
Uses of Funds
4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 58.12 | 1.58 | 212.12 | 11.64 | 88.15 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | -0.05 | -0.21 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 58.12 | 1.58 | 212.12 | 11.58 | 87.94 |
Effect of Exchange Rate Changes | 1.24 | -1.17 | 0.51 | 0.26 | -1.21 |
Net Change In Cash & Equivalents | 25.51 | -19.86 | 34.80 | -16.22 | -19.05 |
Cash at Beginning of Period | 30.73 | 50.59 | 15.79 | 32.01 | 51.06 |
Cash at End of Period | 56.24 | 30.73 | 50.59 | 15.79 | 32.01 |
Diluted Net EPS | -3.33 | -3.36 | -2.42 | -1.64 | -1.38 |
Fiscal Year End for KalVista Pharmaceuticals, Inc falls in the month of April.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -82.00 | -52.97 | -25.32 | -92.91 | -66.60 |
Depreciation/Amortization & Depletion | 0.69 | 0.47 | 0.26 | 1.71 | 1.42 |
Net Change from Assets/Liabilities | -1.44 | -0.41 | -4.22 | 7.41 | 6.28 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.63 | 6.35 | 2.55 | 8.53 | 6.28 |
Net Cash From Operating Activities | -74.13 | -46.56 | -26.73 | -75.26 | -52.63 |
Property & Equipment | -0.03 | -0.01 | -0.01 | -1.20 | -1.13 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 41.79 | 48.38 | 19.62 | 42.61 | 48.75 |
Other Investing Activities | -0.29 | -0.20 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 41.47 | 48.17 | 19.61 | 41.42 | 47.63 |
Uses of Funds
1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.62 | 0.33 | 0.20 | 58.12 | 58.15 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.62 | 0.33 | 0.20 | 58.12 | 58.15 |
Effect of Exchange Rate Changes | -1.14 | -0.52 | 0.08 | 1.24 | 1.17 |
Net Change In Cash & Equivalents | -33.18 | 1.43 | -6.83 | 25.51 | 54.32 |
Cash at Beginning of Period | 56.24 | 56.24 | 56.24 | 30.73 | 30.73 |
Cash at End of Period | 23.06 | 57.67 | 49.41 | 56.24 | 85.05 |
Diluted Net EPS | -0.84 | -0.80 | -0.74 | -0.74 | -0.75 |